NEUP
Neuphoria Therapeutics Inc.
Medical - Pharmaceuticals
Market Cap$23M
5Y Perf.-97.1%
Build Your Comparison
Side-by-side financial analysisNEUP
BIIB
ACAD
PRAX
Try popular comparisons:
Stock Comparison
NEUP vs BIIB vs ACAD vs PRAX
Revenue, margins, valuation, and 5-year total return — side by side.
BIIB
Biogen Inc.
Drug Manufacturers - General
Market Cap$29.02B
5Y Perf.-18.1%
ACAD
ACADIA Pharmaceuticals Inc.
Biotechnology
Market Cap$3.70B
5Y Perf.-7.4%
PRAX
Praxis Precision Medicines, Inc.
Biotechnology
Market Cap$8.15B
5Y Perf.-4.5%
NEUP vs BIIB vs ACAD vs PRAX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  NEUP |  BIIB |  ACAD |  PRAX |
|---|---|---|---|---|
| Industry | Medical - Pharmaceuticals | Drug Manufacturers - General | Biotechnology | Biotechnology |
| Market Cap | $23M | $29.02B | $3.70B | $8.15B |
| Revenue (TTM) | $-10M | $9.86B | $1.10B | $0.00 |
| Net Income (TTM) | $-28M | $1.37B | $376M | $-327M |
| Gross Margin | 100.0% | 69.8% | 91.5% | — |
| Operating Margin | -7.2% | 15.6% | 7.4% | — |
| Forward P/E | — | 13.5x | 55.6x | — |
| Total Debt | $226K | $6.95B | $52M | $110K |
| Cash & Equiv. | $22M | $3.01B | $178M | $357M |
NEUP vs BIIB vs ACAD vs PRAX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NEUP
BIIB
ACAD
PRAX
| Stock | Dec 21 | Jun 26 | Return |
|---|---|---|---|
| Neuphoria Therapeut… (NEUP) | 100 | 2.9 | -97.1% |
| Biogen Inc. (BIIB) | 100 | 81.9 | -18.1% |
| ACADIA Pharmaceutic… (ACAD) | 100 | 92.6 | -7.4% |
| Praxis Precision Me… (PRAX) | 100 | 95.5 | -4.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NEUP vs BIIB vs ACAD vs PRAX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ACAD leads in 3 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Biogen Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. PRAX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
🥇ACAD emerged as the overall leader. Track its performance:
NEUP
Neuphoria Therapeutics Inc.
The Quality Angle
NEUP lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
BIIB
Biogen Inc.
The Income Pick
BIIB is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 0 yrs, beta 0.34
- Better valuation composite
- Beta 0.34 vs PRAX's 1.49
Best for: income & stability
ACAD
ACADIA Pharmaceuticals Inc.
The Growth Play
ACAD carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 11.9%, EPS growth 68.4%, 3Y rev CAGR 27.5%
- Lower volatility, beta 1.08, Low D/E 4.3%, current ratio 3.83x
- Beta 1.08, current ratio 3.83x
- 11.9% revenue growth vs NEUP's -140.1%
Best for: growth exposure and sleep-well-at-night
PRAX
Praxis Precision Medicines, Inc.
The Long-Run Compounder
PRAX is the clearest fit if your priority is long-term compounding.
- -32.3% 10Y total return vs BIIB's -17.2%
- +5.6% vs NEUP's -34.9%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  ACAD | 11.9% revenue growth vs NEUP's -140.1% |
| Value |  BIIB | Better valuation composite |
| Quality / Margins | ACAD | 34.3% margin vs NEUP's -2.4% |
| Stability / Safety | BIIB | Beta 0.34 vs PRAX's 1.49 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) |  PRAX | +5.6% vs NEUP's -34.9% |
| Efficiency (ROA) | ACAD | 26.2% ROA vs NEUP's -77.5%, ROIC 10.0% vs -13.4% |
NEUP vs BIIB vs ACAD vs PRAX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2018
FY 2024
NEUP vs BIIB vs ACAD vs PRAX — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNEUPLAGGINGPRAX
Who Leads Where
NEUP leads in 1 of 6 categories
ACAD leads 1 • PRAX leads 1 • BIIB leads 1 • 1 tied
Explore the data ↓PRAXPraxis Precision Medi…
1leads
ACADACADIA Pharmaceutical…
1leads
BIIBBiogen Inc.
1leads
NEUPNeuphoria Therapeutic…
1leads
6 Total Categories
CATEGORYLEADERvs BIIBvs ACADMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
NEUP3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ACAD4/8
Total Returns1Y, 3Y, 5Y total returns with dividends
PRAX4/6
Risk & VolatilityBeta, volatility, and downside exposure
BIIB2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — NEUP and BIIB and ACAD each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BIIB and NEUP operate at a comparable scale, with $9.9B and -$10M in trailing revenue. ACAD is the more profitable business, keeping 34.3% of every revenue dollar as net income compared to NEUP's -2.4%. On growth, ACAD holds the edge at +9.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| RevenueTrailing 12 months | -$10M | $9.9B | $1.1B | $0 |
| EBITDAEarnings before interest/tax | -$25M | $2.4B | $96M | -$357M |
| Net IncomeAfter-tax profit | -$28M | $1.4B | $376M | -$327M |
| Free Cash FlowCash after capex | $59M | $2.6B | $212M | -$283M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +69.8% | +91.5% | — |
| Operating MarginEBIT ÷ Revenue | -7.2% | +15.6% | +7.4% | — |
| Net MarginNet income ÷ Revenue | -2.4% | +13.9% | +34.3% | — |
| FCF MarginFCF ÷ Revenue | +4.9% | +26.6% | +19.4% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +1.9% | +9.7% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -101.4% | +31.1% | -81.8% | +2.7% |
Evenly matched — NEUP and BIIB and ACAD each lead in 2 of 6 comparable metrics.
Valuation Metrics
NEUP leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 9.4x trailing earnings, ACAD trades at a 58% valuation discount to BIIB's 22.3x P/E. On an enterprise value basis, BIIB's 11.7x EV/EBITDA is more attractive than ACAD's 25.7x.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Market CapShares × price | $23M | $29.0B | $3.7B | $8.2B |
| Enterprise ValueMkt cap + debt − cash | $2M | $33.0B | $3.6B | $7.8B |
| Trailing P/EPrice ÷ TTM EPS | -18.74x | 22.26x | 9.44x | -20.94x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 13.51x | 55.56x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | 11.72x | 25.75x | — |
| Price / SalesMarket cap ÷ Revenue | 1.49x | 2.96x | 3.45x | — |
| Price / BookPrice ÷ Book value/share | 0.24x | 1.58x | 3.02x | 7.24x |
| Price / FCFMarket cap ÷ FCF | 0.30x | 14.15x | 35.20x | — |
NEUP leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
ACAD leads this category, winning 4 of 8 comparable metrics.
Profitability & Efficiency
ACAD delivers a 35.6% return on equity — every $100 of shareholder capital generates $36 in annual profit, vs $-110 for NEUP. PRAX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BIIB's 0.38x. On the Piotroski fundamental quality scale (0–9), NEUP scores 8/9 vs PRAX's 3/9, reflecting strong financial health.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -109.7% | +7.5% | +35.6% | -43.0% |
| ROA (TTM)Return on assets | -77.5% | +4.7% | +26.2% | -40.2% |
| ROICReturn on invested capital | -13.4% | +6.5% | +10.0% | -65.0% |
| ROCEReturn on capital employed | -3.7% | +7.7% | +10.1% | -49.3% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 5 | 6 | 3 |
| Debt / EquityFinancial leverage | 0.01x | 0.38x | 0.04x | 0.00x |
| Net DebtTotal debt minus cash | -$21M | $3.9B | -$126M | -$357M |
| Cash & Equiv.Liquid assets | $22M | $3.0B | $178M | $357M |
| Total DebtShort + long-term debt | $226,487 | $6.9B | $52M | $110,000 |
| Interest CoverageEBIT ÷ Interest expense | — | 6.91x | — | — |
ACAD leads this category, winning 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
PRAX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PRAX five years ago would be worth $8,746 today (with dividends reinvested), compared to $244 for NEUP. Over the past 12 months, PRAX leads with a +557.0% total return vs NEUP's -34.9%. The 3-year compound annual growth rate (CAGR) favors PRAX at 157.7% vs NEUP's -47.9% — a key indicator of consistent wealth creation.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +12.8% | +10.5% | -17.3% | -1.4% |
| 1-Year ReturnPast 12 months | -34.9% | +55.4% | -5.8% | +557.0% |
| 3-Year ReturnCumulative with dividends | -85.8% | -33.1% | -9.3% | +1611.0% |
| 5-Year ReturnCumulative with dividends | -97.6% | -49.4% | -16.9% | -12.5% |
| 10-Year ReturnCumulative with dividends | -97.6% | -17.2% | -42.2% | -32.3% |
| CAGR (3Y)Annualised 3-year return | -47.9% | -12.5% | -3.2% | +157.7% |
PRAX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
BIIB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
BIIB is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than PRAX's 1.49 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BIIB currently trades 95.4% from its 52-week high vs NEUP's 20.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.38x | 0.34x | 1.08x | 1.49x |
| 52-Week HighHighest price in past year | $21.40 | $205.97 | $27.81 | $366.52 |
| 52-Week LowLowest price in past year | $3.65 | $121.05 | $19.69 | $37.19 |
| % of 52W HighCurrent price vs 52-week peak | +20.1% | +95.4% | +77.7% | +77.0% |
| RSI (14)Momentum oscillator 0–100 | 36.3 | 55.2 | 51.4 | 42.5 |
| Avg Volume (50D)Average daily shares traded | 48K | 1.0M | 1.4M | 407K |
BIIB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: BIIB as "Buy", ACAD as "Buy", PRAX as "Buy". Consensus price targets imply 106.9% upside for PRAX (target: $584) vs 11.1% for BIIB (target: $218).
| Metric | NEUPNeuphoria Therape… | BIIBBiogen Inc. | ACADACADIA Pharmaceut… | PRAXPraxis Precision … |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $218.32 | $33.67 | $584.00 |
| # AnalystsCovering analysts | — | 48 | 37 | 16 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NEUP leads in 1 of 6 categories (Valuation Metrics). ACAD leads in 1 (Profitability & Efficiency). 1 tied.
Best OverallNeuphoria Therapeutics Inc. (NEUP)Leads 1 of 6 categories
Loading custom metrics...
NEUP vs BIIB vs ACAD vs PRAX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NEUP or BIIB or ACAD or PRAX a better buy right now?
For growth investors, ACADIA Pharmaceuticals Inc.
(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 4x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate Biogen Inc. (BIIB) a "Buy" — based on 48 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NEUP or BIIB or ACAD or PRAX?
On trailing P/E, ACADIA Pharmaceuticals Inc.
(ACAD) is the cheapest at 9. 4x versus Biogen Inc. at 22. 3x. On forward P/E, Biogen Inc. is actually cheaper at 13. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — NEUP or BIIB or ACAD or PRAX?
Over the past 5 years, Praxis Precision Medicines, Inc.
(PRAX) delivered a total return of -12. 5%, compared to -97. 6% for Neuphoria Therapeutics Inc. (NEUP). Over 10 years, the gap is even starker: BIIB returned -17. 2% versus NEUP's -97. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NEUP or BIIB or ACAD or PRAX?
By beta (market sensitivity over 5 years), Biogen Inc.
(BIIB) is the lower-risk stock at 0. 34β versus Praxis Precision Medicines, Inc. 's 1. 49β — meaning PRAX is approximately 333% more volatile than BIIB relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 38% for Biogen Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — NEUP or BIIB or ACAD or PRAX?
By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.
(ACAD) is pulling ahead at 11. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -130. 0% for Neuphoria Therapeutics Inc.. Over a 3-year CAGR, NEUP leads at 290. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NEUP or BIIB or ACAD or PRAX?
ACADIA Pharmaceuticals Inc.
(ACAD) is the more profitable company, earning 36. 5% net margin versus -2. 4% for Neuphoria Therapeutics Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BIIB leads at 19. 1% versus -7. 2% for NEUP. At the gross margin level — before operating expenses — NEUP leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NEUP or BIIB or ACAD or PRAX more undervalued right now?
On forward earnings alone, Biogen Inc.
(BIIB) trades at 13. 5x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 42. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 106. 9% to $584. 00.
08Which pays a better dividend — NEUP or BIIB or ACAD or PRAX?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is NEUP or BIIB or ACAD or PRAX better for a retirement portfolio?
For long-horizon retirement investors, Biogen Inc.
(BIIB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34)). Both have compounded well over 10 years (BIIB: -17. 2%, PRAX: -32. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NEUP and BIIB and ACAD and PRAX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NEUP is a small-cap quality compounder stock; BIIB is a mid-cap quality compounder stock; ACAD is a small-cap deep-value stock; PRAX is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.